regulator of G protein signaling like 1Genealiases: RGSL · RGSL2
Q-omics provides the consensus-scored RGSL1 profile across patient tissues and cancer cell-line models. RGSL1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, RGSL1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, RGSL1 RNA expression shows 7,396 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ESCA, KIRC, and LSCC as cancer lineages where RGSL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGSL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGSL1 survival associations across molecular data types. RGSL1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGSL1 RNA expression–survival associations across cancer types. High RGSL1 expression shows unfavorable associations in DLBC, KICH, LUAD, UVM and TGCT, but favorable associations in ESCA. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify ESCA as the clearest survival context for RGSL1 RNA expression.
This table summarizes RGSL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RGSL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGSL1 shows lower tumor expression in CHOL and COAD and higher tumor expression in KIRC, LIHC, LUSC and PAAD. The KIRC box plot shows higher RGSL1 RNA expression in tumor versus normal tissue (log2 FC = +0.020, t-test p < 0.001).
This table shows molecular features associated with RGSL1 in patient tissues and cancer cell lines. In patient samples, RGSL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RGSL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
